Biosimilars in Oncology

Market: Pharmaceuticals and Healthcare

Global, 154 pages report, published by GlobalData

Report ThumbnailAugust-2018
Biosimilars in Oncology


Recent trends in drug development have seen the price of new medicines continually increase, and there is a need for cheaper medicines to achieve global sustainable healthcare. Biologic drugs are some of the most expensive medicines to develop, as they are large complex molecules. Biosimilars are highly similar to approved biologic drugs, with no clinically relevant differences, and aim to achieve the same clinical results at a lower price than their originator

Read More
  • Table of Contents
  • 1. Preface 2
  • 1.1 Related Reports 4
  • 1.2 Upcoming Reports 5
  • 1.3 Abbreviations 6
  • 2. Executive Summary 8
  • 3. Introduction 11
  • 3.1 What Is a Biosimilar? 13
  • 3.2 Timeline of Oncology Biosimilar Development by Country in the 7MM 15
  • 3.3 Timeline of Oncology Biosimilar Approvals in India and South Korea 17
  • 4. Biosimilars - Key Clinical and Commercial Concepts 18
  • 4.1 Differences Between Generics and Biosimilars 20
  • 4.2 Differences Between Biosimilarity and Interchangeability 21
  • 4.3 Pricing I
Read More

Please select a license type


Recently Viewed

Related Products

GlobalDataBiosimilars in OncologyProduct ThumbnailBiosimilars in Oncology, Industry ReportProduct #: 1190969
Global Markets Direct
GBI Research
PayPal Acceptance Mark
SSL Certificate
Copyright © 2019 Global Market Analyst. All Rights Reserved